Medicine Overview
Adult Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Mania Age: Adult Condition: Treatment and prevention |
Dose: Oral – 400-1,200 mg daily in 1-2 divided doses Note: Serum lithium should be monitored 12 hours after dose, twice weekly until serum concentration and clinical condition stabilize, and every other month thereafter. Desirable range for serum lithium: 0.6-1.2 mEq/L; although higher serum concentrations may be needed, not to exceed 1.5 mEq/L |
|
Indication: Bipolar disorder Age: Adult Condition: Treatment and prevention |
Dose: Oral – 400-1,200 mg daily in 1-2 divided doses Note: Serum lithium should be monitored 12 hours after dose, twice weekly until serum concentration and clinical condition stabilize, and every other month thereafter. Desirable range for serum lithium: 0.6-1.2 mEq/L; although higher serum concentrations may be needed, not to exceed 1.5 mEq/L |
Child Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Bipolar I Disorder (Acute Manic or Mixed Episodes and Maintenance Treatment) Age: 7 years and older |
Dose: Tablet – 300 mg Frequency: Three times daily Note: by mouth (oral) |
|
Indication: Bipolar I Disorder (Acute Manic or Mixed Episodes and Maintenance Treatment) Age: 7 years and older |
Dose: Tablet – 300 mg Frequency: twice daily Note: by mouth (oral) |
Renal Dose
| Clinical Information | Administration Information |
|---|---|
|
Condition: Renal impairment: Creatinine Clearance 10-50 ml/min |
Dose: Dosage Form with Dose – 50-75% of normal dose Note: Renal impairment dosage recommendation |
|
Condition: Renal impairment: Creatinine Clearance less than 10 ml/min |
Dose: Dosage Form with Dose – 25-50% of normal dose Note: Renal impairment dosage recommendation |
Administration
- Take with food
- Regular timing
Side Effect
- Leukocytosis (most patients)
- Polyuria/polydypsia (30-50%)
- Dry mouth (20-50%)
- Hand tremor (45% initially
- 10% after 1 year of treatment)
- Confusion (40%)
- Decreased memory (40%)
- Headache (40%)
- Muscle weakness (30% initially
- 1% after 1 year of treatment)
- Electrocardiographic (ECG) changes (20-30%)
- Nausea
- vomiting
- diarrhea (10-30% initially
- 1-10% after 1-2 years of treatment)
- Hyperreflexia (15%)
- Muscle twitch (15%)
- Vertigo (15%)
- Extrapyramidal symptoms
- goiter (5%)
- Hypothyroidism (1-4%)
- Acne (1%)
- Hair thinning (1%)
- Coma
- Lethargy
- Seizures
- Renal toxicity
Drug Interaction
Drug Interaction
| Drug Name | Risk Factors |
|---|---|
|
Carbonic Anhydrase Inhibitors (Acetazolamide, Dorzolamide, Brinzolamide), Chlorpromazine, Sodium-containing preparations, Theophylline, Urea
|
Reduced serum levels
|
|
Iodine salts
|
Enhanced hypothyroid effects
|
Disease Interaction
Disease Interaction
| Disease Name | Risk Factors |
|---|---|
|
Renal insufficiency
|
Risk of lithium toxicity
|
|
Cardiovascular insufficiency
|
Can worsen heart function
|
Pregnancy
Pregnancy
Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage
Store at 25° C
Data Sources
Clinical & regulatory information on this page is compiled from the following government sources:
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.